National Vision (EYE)
(Delayed Data from NSDQ)
$13.61 USD
+0.41 (3.11%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $13.61 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.61 USD
+0.41 (3.11%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $13.61 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Zacks News
Medtronic Displays All-Business-Line Growth Despite Cost Woes
by Zacks Equity Research
Medtronic's (MDT) Diabetes group is expanding internationally on the strong rollout of its MiniMed 670G in untapped markets.
Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark
by Zacks Equity Research
Hologic (HOLX) wins the CE Mark for long-term use of LOCalizer RFID tag, providing more flexibility to breast-conserving surgery.
QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus
by Zacks Equity Research
QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.
Neogen's (NEOG) Food Safety Test Receives AOAC Clearance
by Zacks Equity Research
Neogen's (NEOG) Reveal 3-D safety test for checking peanut contamination in food items gets approval from the AOAC.
Bio-Rad's Blood Typing Market Growth Strong on New Products
by Zacks Equity Research
Bio-Rad's (BIO) new product acceptance in the United States is a positive with the recent 510(k) clearance of the IH-Reader 24.
Amedisys (AMED) to Broaden Hospice Base With Asana Purchase
by Zacks Equity Research
Asana's acquisition to be the third hospice care buyout of Amedisys (AMED) in 2019.
Medtronic Gets FDA Nod for IN.PACT AV for ESRD Patients
by Zacks Equity Research
Medtronic (MDT) receives FDA clearance for IN.PACT AV for the treatment of arteriovenous failures in patients undergoing hemodialysis.
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.
NuVasive Gets FDA Nod for CoRoent Small Interlock System
by Zacks Equity Research
NuVasive (NUVA) receives the FDA clearance for expanded use of its Interlock system for minimally disruptive spine surgery at multiple levels.
Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds
by Zacks Equity Research
Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.
EYE vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
EYE vs. LMAT: Which Stock Is the Better Value Option?
National Vision's (EYE) Q3 Earnings Top Estimates, View Raised
by Zacks Equity Research
National Vision's (EYE) third-quarter performance reflects strong growth in core business segments.
National Vision (EYE) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 50.00% and 1.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Reports Next Week: What You Should Expect
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EYE vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. LMAT: Which Stock Is the Better Value Option?
GNC Holdings Inks Retail Partnership Deal to Grow in Brazil
by Zacks Equity Research
We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.
National Vision (EYE) Down 11.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Innovation Aids Genomic Health, Merger Procedure on Track
by Zacks Equity Research
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
Insulet (PODD) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Insulet (PODD) has various favorable factors to maintain the current high.
National Vision's Store Launches on Track Despite Cost Woes
by Zacks Equity Research
National Vision (EYE) adopts a formula-based approach to open around 75 stores in 2019.
Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety
by Zacks Equity Research
Neogen's (NEOG) proprietary testing platform gets upgraded to reduce the incidence of bacterial contamination in livestock.
NuVasive's New TLIF Implant Broadens Spine Surgery Option
by Zacks Equity Research
NuVasive's (NUVA) Modulus TLIF-A is designed to work smoothly with the existing MAS TLIF and MAS Midline access systems.
EYE vs. HAE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. HAE: Which Stock Is the Better Value Option?
Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod
by Zacks Equity Research
Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.
Baxter (BAX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.